Stuttgart - Delayed Quote • EUR Organigram Holdings Inc. (0OG0.SG) Follow Compare 1.4500 -0.0160 (-1.09%) As of 9:10:17 AM GMT+1. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Why OrganiGram (OGI) Is Among the Best Pot Stocks to Invest in According to Analysts? We recently compiled a list of the 10 Best Pot Stocks To Invest In According to Analysts. In this article, we are going to take a look at where OrganiGram (NASDAQ:OGI) stands against other pot stocks to buy according to analysts. The global marijuana market is growing and the market for legal cannabis is expected […] Organigram Reports Fourth Quarter and Fiscal 2024 Results TORONTO, December 20, 2024--This earnings release replaces the previously filed earnings release on December 18, 2024 to correct errors in the outstanding share data tables under the heading "CAPITAL STRUCTURE." No other changes are being made. The Company is also refiling its Management’s Discussion and Analysis for the twelve months ended September 30, 2024 to correct corresponding errors in the outstanding share data table, which corrections will also apply to the MD&A included in the Company OrganiGram Holdings Inc (OGI) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... OrganiGram Holdings Inc (OGI) reports a 22% year-over-year revenue increase and strategic international expansions, despite a net loss improvement. Organigram (OGI) Q4 2024 Earnings Call Transcript OGI earnings call for the period ending September 30, 2024. OrganiGram: Fiscal Q4 Earnings Snapshot TORONTO (AP) — OrganiGram Holdings Inc. OGI) on Wednesday reported a loss of $4 million in its fiscal fourth quarter. The Toronto-based company said it had a loss of 4 cents per share. Organigram Acquires Motif Labs, Becomes Canada’s Largest Cannabis Company OrganiGram Holdings ( (TSE:OGI) ) just unveiled an announcement. Organigram Holdings Inc. announced the acquisition of Motif Labs Ltd., establishing itself as Canada’s largest cannabis company by market share. This strategic acquisition enhances Organigram’s position in the Canadian recreational cannabis market, particularly in the vape and infused pre-roll segments, and supports its vision to expand globally. The acquisition is expected to generate significant cost synergies and improve market Organigram to Report Fourth Quarter and Fiscal 2024 Results on December 18, 2024 TORONTO, December 11, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open. Weekly Roundup on the Cannabis Sector & Psychedelic Sector Key Takeaways; Cannabis Sector Organigram acquired Motif Labs in a transformational move that will make the company Canada’s new cannabis leader Safe Harbor Financial leads the charge in sustainable cannabis financing with $500K loan Rubicon Organics secured CA$10 million in credit to strengthen its financial position Glass House Brands is seeking $25 million for expansion […] Organigram Up 2% In US Premarket As Buys Motif; Says To Become Canada's "Largest Cannabis Company by Market Share" Organigram Holdings Inc. (NASDAQ and TSX: OGI), a licensed producer of cannabis, was up 2% in US pre Organigram Acquires Motif, Becoming Canada’s Largest Cannabis Company by Market Share TORONTO, December 06, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce the acquisition of 100% of the issued and outstanding shares of Motif Labs Ltd. ("Motif"), for upfront consideration of $90 million, consisting of $50 million in cash and $40 million of Organigram common shares priced based on the 30 day trading VWAP of $2.3210 on the Toronto Stock Exchange ("TSX"). In addition, Motif shar Organigram Launches FAST™ Nanoemulsion Gummies TORONTO, November 26, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram’s inaugural product powered by FAST™, the Company’s groundbreaking nanoemulsion technology and a first-to-market innovation. Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment TORONTO, September 03, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the "Second Tranche") of the previously announced C$124,559,674 follow-on strategic equity investment (the "Investment") by BT DE Investments Inc. (the "Investor"), a wholly owned subsidiary of British American Tobacco plc ("BAT"). Pursuant to the Second T Organigram (OGI) Q3 2024 Earnings Call Transcript OGI earnings call for the period ending June 30, 2024. OrganiGram: Fiscal Q3 Earnings Snapshot TORONTO (AP) — OrganiGram Holdings Inc. OGI) on Tuesday reported fiscal third-quarter earnings of $2.1 million. On a per-share basis, the Toronto-based company said it had net income of 2 cents. Organigram Up 4.9% in U.S. Premarket After Q3 Profit Figures Released Organigram Up 4.9% in U.S. Premarket After Q3 Profit Figures Released Organigram Reports Third Quarter Fiscal 2024 Results TORONTO, August 13, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 ("Q3 Fiscal 2024"). Organigram Says Product Development Collaboration Completes Clinical Study on Nanoemulsion Technology Organigram Says Product Development Collaboration Completes Clinical Study on Nanoemulsion Technology Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology TORONTO, August 07, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading licensed producer of cannabis, is pleased to unveil the preliminary results of its landmark clinical pharmacokinetic (PK) study conducted via the Product Development Collaboration (PDC) on its latest innovation, nanoemulsion technology. This patent-pending technology, branded FAST™ (Fast Acting Soluble Technology), will be the first innovation to be commercialized by Organigram leveraging the output of the PDC Organigram to Report Third Quarter Fiscal 2024 Results on August 13, 2024 TORONTO, August 06, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open. Performance Overview Trailing total returns as of 1/24/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return 0OG0.SG S&P/TSX Composite index YTD -3.72% +3.30% 1-Year -15.20% +20.92% 3-Year -71.88% +23.34%